Welcome back to Endpoints Weekly. Endpoints News broke the news this week on the deaths of three patients who received Novartis’ experimental CAR-T therapy. Novartis has paused immunology and neuroscience ...
September 5, 2026 06:00 AM EDT
Weekly
CAR-T deaths prompt halt by Novartis; Eli Lilly’s 13th acquisition of 2026; and more
Nicole DeFeudis
Welcome back to Endpoints Weekly. Endpoints News broke the news this week on the deaths of three patients who received Novartis’ experimental CAR-T therapy. Novartis …
Novartis halts CAR-T trials after three patient deaths from an immune overreaction; Bristol Myers pauses zola-cel enrollment.
Three patient deaths in Novartis' autoimmune CAR-T trials raise questions about risks of the therapy in non-fatal diseases.
Novartis, BMS reportedly halt trials; first serious blow to burgeoning field
Welcome back to Endpoints Weekly! Merck and Moderna dominated the headlines this week with topline results for their personalized…
Welcome back to Endpoints Weekly! The big news this week was the FDA’s approval of Revolution Medicines’ pancreatic cancer…
Novartis paused 8 trials of its rap-cel therapy after patients died from a severe immune reaction; Bristol Myers followed as a…
Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts
